Please assess the completion status of the following clinical trial:

Trial Title: Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Absolute neutrophil count \>= 1,500/mm3~* No psychiatric illness or social situation that would preclude study compliance~* Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and investigational or targeted therapies (i.e., inhibitors of the epidermal growth factor receptor) will not count toward the maximum of 2 prior regimens allowed~* Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or extrahepatic bile duct or gallbladder:~  * Locally advanced or metastatic disease~* At least 1 unidimensionally measurable lesion \>=20 mm by conventional techniques OR \>= 10 mm by spiral CT scan~* Not amenable to curative surgical resection~* No known brain metastases~* Performance status:~  * ECOG 0-2~* Life expectancy:~  * More than 12 weeks~* Platelet count \>= 100,000/mm3~* WBC \>= 3,000/mm3~* AST and ALT ≤ 2.5 times upper limit of normal (ULN) \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\]~* Bilirubin ≤ 1.5 times ULN \[Note: Biliary shunting or stenting allowed to achieve the required bilirubin and transaminase levels\]~* Creatinine within ULN OR Creatinine clearance \>= 60 mL/min~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No symptomatic cardiac arrhythmia within the past 4 weeks~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No underlying neuropathy \>= grade 2~* No history of allergic reaction to boron, mannitol, or bortezomib~* No active or ongoing infection~* No concurrent uncontrolled illness~* No medical or psychiatric condition that would preclude study participation~* No prophylactic granulocyte or platelet growth factors (filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])~* Prior chemotherapy as a radiosensitizer (e.g., fluorouracil or gemcitabine) with radiotherapy is allowed as adjuvant therapy after resection for locally advanced disease provided there is evidence of disease progression~* No more than 2 prior chemotherapy regimens for locally advanced or metastatic disease~* No concurrent combination antiretroviral therapy for HIV-positive patients~* No other concurrent anticancer agents or therapies~* No other concurrent investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.

Based on this trial design, predict the completion outcome and termination type (if applicable).